Bosutinib - an effective and safe treatment option in the management of chronic myeloid leukemia.

Ercaliskan A., Eskazan A. E.

Future oncology (London, England), cilt.16, ss.4425-4428, 2020 (SCI-Expanded, Scopus)

• Yayın Türü: Makale / Editöre Mektup
• Cilt numarası: 16
• Basım Tarihi: 2020
• Doi Numarası: 10.2217/fon-2020-0006
• Dergi Adı: Future oncology (London, England)
• Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, CINAHL, EMBASE, MEDLINE
• Sayfa Sayıları: ss.4425-4428
• Anahtar Kelimeler: adverse event, bosutinib, chronic myeloid leukemia, comorbidity, imatinib, tyrosine kinase inhibitor, KINASE INHIBITOR TKI, IMATINIB, DASATINIB, DISCONTINUATION, NILOTINIB, THERAPY, CML
• İstanbul Üniversitesi-Cerrahpaşa Adresli: Evet